Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
7.69M |
$146M |
$19.00 |
Jun 28, 2021 |
Indirect |
Savara Inc |
10%+ Owner |
Common Stock |
24.5M |
$109M |
$4.45 |
Jul 17, 2023 |
Indirect |
Korro Bio, Inc. |
10%+ Owner |
Common Stock |
1.09M |
$61.1M |
$56.00 |
Apr 22, 2024 |
Indirect |
RHYTHM PHARMACEUTICALS, INC. |
Director |
Common Stock |
5.77K |
$226K |
$39.10 |
Jun 21, 2024 |
Indirect |
RHYTHM PHARMACEUTICALS, INC. |
Director |
Common Stock |
3K |
$117K |
$39.10 |
Jun 21, 2024 |
Direct |
RHYTHM PHARMACEUTICALS, INC. |
Director |
Restricted Stock Units |
0 |
$0 |
$39.10 |
Jun 21, 2024 |
Direct |
MBX Biosciences, Inc. |
Director, 10%+ Owner |
Common Stock |
3.61M |
|
|
Sep 16, 2024 |
Indirect |
NeueHealth, Inc. |
10%+ Owner |
Warrant (Right to Buy) |
557K |
|
|
Oct 1, 2024 |
Indirect |
Senti Biosciences, Inc. |
Director |
Stock Option (Right to Buy) |
62.5K |
|
|
Jul 10, 2024 |
Direct |
SYNLOGIC, INC. |
Director |
Stock Option (right to buy) |
30K |
|
|
Jun 22, 2023 |
Direct |
Trevi Therapeutics, Inc. |
Director |
Nonstatutory Stock Option (right to buy) |
30K |
|
|
Jun 13, 2024 |
Direct |
Inozyme Pharma, Inc. |
Director |
Stock Option (right to buy) |
28K |
|
|
Jun 18, 2024 |
Direct |
Mirum Pharmaceuticals, Inc. |
Director |
Stock Option (right to buy) |
17K |
|
|
Jun 2, 2022 |
Direct |
MBX Biosciences, Inc. |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
16K |
|
|
Sep 12, 2024 |
Direct |
Reneo Pharmaceuticals, Inc. |
Director |
Stock Option (right to buy) |
15.3K |
|
|
Oct 4, 2024 |
Direct |
RHYTHM PHARMACEUTICALS, INC. |
Director |
Stock Option (right to buy) |
14K |
|
|
Jun 18, 2024 |
Direct |
Akouos, Inc. |
Director |
Stock Option (right to buy) |
0 |
|
|
Dec 1, 2022 |
Direct |
MBX Biosciences, Inc. |
Director, 10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
Indirect |
MBX Biosciences, Inc. |
Director, 10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
Indirect |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series A-2 convertible preferred stock |
0 |
|
|
Jun 28, 2021 |
Indirect |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
Indirect |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series C convertible preferred Stock |
0 |
|
|
Jun 28, 2021 |
Indirect |